Lucid Diagnostics Inc (LUCD) saw an uptrend of 715392% in the recent trading with $1200000.0 being its most recent. The current price level -33.89% lower than the highest price of $1.80 marked by the stock while trading over the past 52-weeks, whereas it is 65.25% higher than the lowest price of $0.72 the company dropped to over past 52-weeks. The latest news story on LUCD appeared in (PR Newswire) under the title “Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics’ EsoGuard® Esophageal DNA Test” on Jun-18-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Lucid Diagnostics Inc Earnings – What Happened With LUCD
Coming around sales and income figures on LUCD Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Lucid Diagnostics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 84.37 million. LUCD does have institutional investors; and they hold 9.78% of the stock.
As on 2024-06-30, LUMINUS MANAGEMENT LLC was the top most holder in Lucid Diagnostics Inc (NASDAQ:LUCD) with an ownership of 0.73 million shares of the company or 1.6124 of the stake worth $0.6 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 1.2461 of the outstanding shares. Its stake is worth $0.46 million for having 0.56 million shares in hand.
GEODE CAPITAL MANAGEMENT, LLC also came holding a key position in the company during the recent quarter and it now holds 0.454 of the outstanding shares. With this there are now 53.0 institutions which have possession in LUCD’s shares.
Key Metrics forLUCD
Technical Analysis of Lucid Diagnostics Inc (NASDAQ:LUCD) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Lucid Diagnostics Inc (LUCD), we notice that the stock’s 20-day average volume is at 1,085,045 shares and 50% of short term indicators are suggesting the stock as Sell. And to end, LUCD’s 100-day average volume is 1,081,089 shares with 50% of the long-term indicators pointing towards Buy for the stock.
